Articles From: Manning & Napier, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results to ManpowerGroup Chairman Emeritus, Mitchell Fromstein, Passes Away at Age 85


2014/1/23
Manning & Napier, Inc. (NYSE: MN), (“Manning & Napier” or “the Company”) today announced that it will host a teleconference to discuss the Company’s 2013 fourth quarter and year-end financial results at 8:00 a.m. ET on Thursday, February 13, 2014.
Sign-up for Manning & Napier, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results investment picks
Manning & Napier, Inc. (NYSE:MN), (“Manning & Napier” or “the Company”) today announced that it will host a teleconference to discuss the Company’s 2013 third quarter financial results at 8:00 a.m. ET on Thursday, October 31, 2013.
Sign-up for Manning & Napier, Inc. to Report Third Quarter 2013 Financial Results investment picks
2013/10/30
MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for AFREZZA ® (insulin human [rDNA origin]) Inhalation Powder.
Sign-up for MannKind Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA investment picks
MannKind Corporation (Nasdaq:MNKD) today announced that it will hold a conference call at 4:00 pm (EDT) today to discuss preliminary results from Study 171 and Study 175, two Phase 3 clinical studies of AFREZZA ® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy administered using MannKind’s next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler). Highlights of Study 171 In patients with type 1 diabetes, AFREZZA, compared to insulin aspart, showed: Non-inferior decreases in A1c levels; Significantly less hypoglycemia; Significant decreases in fasting blood glucose levels; and Significant weight advantage.
Sign-up for MannKind Announces Positive Clinical Data for AFREZZA; Both AFFINITY Phase 3 Studies Meet Primary Endpoints investment picks
2014/1/10
VALENCIA, Calif., Jan.
Sign-up for MannKind Announces Tentative Date of FDA Advisory Committee Review of AFREZZA investment picks
2014/2/18
VALENCIA, Calif., Feb.
Sign-up for MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results investment picks
2013/8/9
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2013.
Sign-up for MannKind Corporation Reports 2013 Second Quarter Financial Results investment picks
2014/2/4
VALENCIA, Calif., Feb.
Sign-up for MannKind Corporation to Hold 2013 Fourth Quarter and Full Year Financial Results Conference Call on February 18, 2014 investment picks
MannKind Corporation (Nasdaq: MNKD) will release its 2013 third quarter financial results on Monday, November 4, 2013 and its management will host a conference call to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 4, 2013.
Sign-up for MannKind Corporation to Hold 2013 Third Quarter Financial Results Conference Call on November 4, 2013 investment picks
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 14, 2013 at 11:30 AM (ET) at the Westin Grand Central in New York City.
Sign-up for MannKind Corporation to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum investment picks
2013/9/3
MannKind Corporation (Nasdaq: MNKD) , focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 3:30 PM (ET) at the Grand Hyatt Hotel in New York City.
Sign-up for MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference investment picks
2014/1/8
VALENCIA, Calif., Jan.
Sign-up for MannKind Corporation to Present at the J.P. Morgan 2014 Healthcare Conference investment picks
MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at The Piper Jaffray 25th Annual Healthcare Conference on Wednesday, December 4, 2013 at 10:00 AM (ET) at The New York Palace, New York, New York.
Sign-up for MannKind Corporation to Present at The Piper Jaffray 25th Annual Healthcare Conference investment picks
2014/2/19
VALENCIA, Calif., Feb.
Sign-up for MannKind Corporation to Present at Upcoming Conferences investment picks
2014/4/7
NEW YORK (MarketWatch) -- Shares in MannKind Corp.
Sign-up for MannKind drops 12% after FDA review extension investment picks
2013/8/14
MannKind Corporation (Nasdaq: MNKD) today announced positive preliminary results from Study 175, a Phase 3 clinical study of AFREZZA ® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy administered using MannKind’s next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler), in patients with type 2 diabetes.
Sign-up for MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes investment picks
2013/10/14
MannKind Corporation (Nasdaq: MNKD) today announced the resubmission on October 13, 2013 of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of AFREZZA ® (insulin human [rDNA origin]) Inhalation Powder with an indication to improve glycemic control in adults with type 1 or type 2 diabetes.
Sign-up for MannKind Resubmits New Drug Application to U.S. FDA for AFREZZA for the Treatment of Adults with Diabetes investment picks
2013/8/16
MannKind Corporation (Nasdaq: MNKD) today announced that, pursuant to a Facility Agreement (the “Facility Agreement”) dated July 1, 2013 between Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and MannKind, the conditions that obligate Deerfield to purchase the second $40 million tranche of 9.75% senior secured convertible notes (the “Convertible Notes”) have now been satisfied.
Sign-up for MannKind Satisfies Conditions for Second Tranche of Convertible Note Financing investment picks
2014/4/7
VALENCIA, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA ® by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA's requests.
Sign-up for MannKind Updates Status of New Drug Application for AFREZZA(R) investment picks
2014/4/2
By Saumya Vaishampayan, MarketWatch NEW YORK (MarketWatch) -- Shares of MannKind Corp.
Sign-up for MannKind, Ingersoll-Rand gain; Apollo Education falls investment picks
2014/3/11
Signs of Stabilization in Europe; Indian Employers Predict Vigorous Hiring Pace MILWAUKEE, Wis.
Sign-up for Manpower Employment Outlook Survey Points to Uptick in Hiring Confidence Around the World investment picks
Employers Optimistic About Fourth Quarter Job Prospects Amid Continued Economic Uncertainty MILWAUKEE , Sept.
Sign-up for Manpower Employment Outlook Survey Reports Improved Year-End Hiring Plans in U.S., Strongest Since Q4 2007 investment picks
2014/3/11
Number of Employers Anticipating Workforce Reductions Sinks to Historic Survey Low MILWAUKEE , March 11, 2014 /PRNewswire/ -- The latest Manpower Employment Outlook Survey , released today by ManpowerGroup, reaffirms continued hiring confidence in the second quarter of 2014, as U.S. employers report a seasonally adjusted Net Employment Outlook of +13%. This is the third consecutive quarter with a Net Employment Outlook of +13%, which is the strongest Outlook since Quarter 2 2008 when the Outlook was +14%. The Quarter 2 Outlook is slightly stronger than one year ago when the Outlook was +11%. Of the more than 18,000 employers surveyed, 19 percent anticipate an increase in staff levels in their Quarter 2 2014 hiring plans, while anticipated staff reductions are among the lowest in survey history at 4 percent.
Sign-up for Manpower Employment Outlook Survey Reports Stable U.S. Hiring Plans for Quarter 2 2014 investment picks
2013/12/10
Manpower Employment Outlook Survey Reveals Canadian Employers Anticipate a Steady Hiring Climate for the First Quarter of 2014; Job Prospects Strongest in Construction Canada NewsWire TORONTO , Dec.
Sign-up for Manpower Employment Outlook Survey Reveals Canadian Employers Anticipate a Steady Hiring Climate for the First Quarter of 2014; Job Prospects Strongest in Construction investment picks
Data Reflects Strongest Quarter 1 Intent to Hire Since 2008 MILWAUKEE , Dec.
Sign-up for Manpower Employment Outlook Survey Reveals Stable U.S. Hiring Plans for Quarter 1 2014 investment picks
U.S. Outlook Strongest in Over Five Years; Europe Hiring Intentions Soften MILWAUKEE , Sept.
Sign-up for Manpower Employment Outlook Survey Shows Most Global Employers to Adopt Wait-and-See Approach to Hiring for Rest of Year investment picks
U.S. Bureau of Labor Statistics Reports a 7.3% Jobless Rate and 204,000 Jobs Added in October MILWAUKEE , Nov.
Sign-up for ManpowerGroup Advises CEOs to Access, Mobilize and Optimize Talent to Remain Competitive in Economic Uncertainty investment picks
2014/2/7
U.S. Bureau of Labor Statistics Reports 113,000 Jobs Added in January MILWAUKEE , Feb.
Sign-up for ManpowerGroup Advises Employers to Diversify Work Models to Enhance Organizational Agility investment picks
Changing Lives and Transforming Communities by Connecting People to Meaningful Work Since 1948 MILWAUKEE , Oct.
Sign-up for ManpowerGroup Celebrates 65 Years of Ensuring the Talent Sustainability of the World's Workforce investment picks
Fromstein, Milwaukee Business Leader, was a Staffing Industry Champion MILWAUKEE , Nov.
Sign-up for ManpowerGroup Chairman Emeritus, Mitchell Fromstein, Passes Away at Age 85 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Manning & Napier, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results to ManpowerGroup Chairman Emeritus, Mitchell Fromstein, Passes Away at Age 85
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity